Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada

References

• Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol. 2008;26(1):8–20.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–6767.
   PubMed Web of Science ®Google Scholar
• Brenner DR, Weir HK, Demers AA, et al. Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199–e205.
   PubMed Web of Science ®Google Scholar
• Mahe ER, Pugh T, Stockley T, et al. Filling the void of Canadian T-cell lymphoma epidemiology: data from the Canadian Institute for Health Information discharge abstract database. Am Assoc Cancer Res. 2015;75:15.
   Google Scholar
• d’Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108–15. Sep
   PubMedGoogle Scholar
• Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood. 2014;123(17):2636–2644.
   PubMed Web of Science ®Google Scholar
• Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris). 2018.
   Google Scholar
• Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris) for HL 2013. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-adcetrishl-fn-rec.pdf
   Google Scholar
• Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation (Adcetris) for sALCL 2013. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-rec.pdf
   Google Scholar
• L’Institut National d'Excellence En Santé Et En Services Sociaux. ADCETRISMC – lymphome anaplasique à grandes cellules systémique 2014. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Fevrier_2014/adcetris_lagcs_2014_02_CAV.pdf
   Google Scholar
• L’Institut National d'Excellence En Santé Et En Services Sociaux. ADCETRISMC – lymphome de Hodgkin 2014. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Juin_2014/Adcetris__LH_2014_06_CAV.pdf
   Google Scholar
• L’Institut National d'Excellence En Santé Et En Services Sociaux. ADCETRISMC – lymphome de Hodgkin 2018. Available from: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Fevrier_2018/Adcetris_2018_02.pdf
   Google Scholar
• Adcetris [Product Monograph]. Bothell, WA: Seagen Inc.; 2019.
   Google Scholar
• Federico M, Bellei M, Luminari S, et al. CD30+ expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-Cell Project. J Clin Oncol. 2015;33(15_suppl):8552–8552.
   Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
   PubMed Web of Science ®Google Scholar
• Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2021;2021:S0923-7534(21)04875-4.
   Google Scholar
• Horowitz SM, O’Connor OA, Pro B, et al., editors. The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A + CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. 62nd ASH Annual Meeting and Exposition; 2020 December 5–8; Virtual.
   Google Scholar
• Hux M, Zou D, Ma E, et al. Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma. J Clin Oncol. 2016;34(7_suppl):18–18.
   Web of Science ®Google Scholar
• Feldman T, Zou D, Rebeira M, et al. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020;26(2):e41–e49.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 4th edition. 2017.
   Google Scholar
• Seagen Inc. Document on file – Cost-effectiveness of brentuximab vedotin for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma, peripheral T-cell lymphomas not otherwise specified, or angioimmunoblastic T-cell lymphoma whose tumors express CD30: Canadian pCODR technical report. 2019.
   Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754.
   PubMed Web of Science ®Google Scholar
• Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, international T-Cell Project. Haematologica. 2018;103(7):1191–1197.
   PubMed Web of Science ®Google Scholar
• Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507–1517.
   PubMed Web of Science ®Google Scholar
• EuroQol Research Foundation. EQ-5D-3L User Guide. 2018. [June 8, 2021].
   Google Scholar
• Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) final recommendation for brentuximab vedotin (Adcetris) for peripheral T-cell lymphoma 2020. Available from: https://cadth.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf
   Google Scholar
• NEUPOGEN (filgrastim) [package insert]. U.S. Food and Drug Administration website 2015 [cited 2021 Mar 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf
   Google Scholar
• ADCETRIS (brentuximab vedotin) [package insert] U.S. Food and Drug Administration website 2014. [cited 2021 Mar 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf
   Google Scholar
• Ontario Ministry of Health and Long-Term Care (MOHLTC). Schedule of benefits. Physician services. [cited 2019 Mar 20]. Available from: https://www.health.gov.on.ca/en/pro/programs/ohip/sob/
   Google Scholar
• Ontario Ministry of Health and Long-Term Care (MOHLTC). Interprovincial billing rates for designated high cost transplants effective for discharges on or after April 1, 2018. 2018 [cited 2019 Mar 20]. Available from: https://www.health.gov.on.ca/en/pro/programs/ohip/bulletins/na_84/high_cost_procedures.pdf
   Google Scholar
• Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care. 2011;27(2):79–88.
   PubMed Web of Science ®Google Scholar
• Costa S, Scott DW, Steidl C, et al. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia. Curr Oncol. 2019;26(2):108–113.
   PubMed Web of Science ®Google Scholar
• Ontario Case Costing Initiative. Cost analysis tool – Acute inpatient and ambulatory 2016/2017 statistics by most responsible diagnosis [March] 2019.
   Google Scholar
• Briggs AH, Schulpher CK. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006.
   Google Scholar
• Woods B, Sideris E, Palmer N, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017. [January 3, 2019].
   Google Scholar
• Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health. 2010;13(6):837–845.
   PubMed Web of Science ®Google Scholar
• Ontario Case Costing Initiative. Cost analysis tool – Acute inpatient and ambulatory 2016/2017 statistics by most responsible diagnosis [March 2019].
   Google Scholar